|
| Study | ATB mixture | Vehicle | Ratio | Irrigants | Restoration | Final follow-up (months) | Clinical outcomes | Exfoliation | Radiographical outcomes |
| Pain | Swelling/fistula | Abscess | Pain in percussion | Mobility | Bone regeneration | Increased radiolucency | No changes |
|
Pinky et al. [13]
India/2011 | Ciprofloxacin-metronidazole-minocycline | Propylene glycol | 1 : 3 : 3 | Saline | Temporary dressing with zinc oxide eugenol/stainless steel crowns (after 30 days) | 12 | 2 (10%) | — | — | — | — | — | 11 (55%) | 2 (10%) | 7 (35%) |
| Ciprofloxacin-minocycline-ornidazole | 1 : 3 : 3 | — | — | — | — | — | — | 12 (60%) | — | 8 (40%) |
Nanda et al. [14]
India/2014 | Ciprofloxacin-metronidazole-minocycline | Propylene glycol | 1 : 3 : 3 | Saline | Glass ionomer cement/stainless steel crowns (at the same visit) | 12 | — | — | — | — | — | — | 6 (30%) | 3 (15%) | 7 (35%) |
| Ciprofloxacin-minocycline-ornidazole | 1 : 3 : 3 | — | — | — | — | — | 7 (35%) | 4 (20%) | 1 (5%) |
Singh et al. [16]
India/2017 | Ciprofloxacin-metronidazole-minocycline | Propylene glycol | 1 : 3 : 3 | Saline | Temporary dressing (zinc oxide eugenol/glass ionomer cement (after 15 days)/stainless steel crowns (after 30 days)) | 12 | 2 (5%) | — | — | — | 2 (5%) | — | 22 (55%) | 4 (10%) | 14 (35%) |
| Ciprofloxacin-minocycline-ornidazole | 1 : 3 : 3 | — | — | — | — | — | 24 (60%) | — | 16 (14%) |
Jaya et al. [15]
India/2012 | Ciprofloxacin-metronidazole-minocycline | Propylene glycol/macrogol | 1 : 3 : 3 | Saline | Glass ionomer cement/stainless steel crowns (at the same visit) | 24 | — | — | — | — | 8 (62%). | — | Nm | 9 (69%). | Nm |
| Ciprofloxacin-tinidazole-minocycline | 1 : 3 : 3 | — | — | — | — | 7 (50%) | Nm | 8 (57%) | Nm |
Raslan et al. [17]
Syria/2017 | Ciprofloxacin-metronidazole-minocycline | Propylene glycol | 1 : 1 : 1 | Phosphoric acid/sterile water | Glass ionomer cement/stainless steel crowns (at the same visit) | 12 | — | 1 (3, 6%) | 2 (9, 52%) | — | — | 3 (16.67%) | 11 (61.11%) | 1 (5.56%) | 3 (16.67) |
| Ciprofloxacin-metronidazole-clindamycin | 1 : 1 : 1 | — | — | 1 (3, 52%) | — | — | 2 (10%) | 11 (55%) | 4 (20%) | 3 (15%) |
|
